Sunday, 13 January 2019

CPD Applicable- Biomarkers Congress 2019
International Conference on Biomarkers and Clinical Research
July 15-16, 2019 Abu Dhabi, UAE

Medical conferences play a critically important role in the continuing education of physicians, technicians, nurses, and other health care professionals. There are many functions which these conferences meet including following benefits:

· Focus on sharpening the skills

· Meet professional “idols” face-to-face

· Try “new tools” in the armamentarium and evolving novel and locally relevant ideas

· Breakout from psychological ease zone into a new space which often sparks new ideas encouraging developing consensus in contentious areas all leading to improvement in health-care delivery, and patient outcomes

· Meet likeminded individuals, in person, to sort out issues and help build consensus on contentious issues.

· Exposure to other professionals may encourage physicians to improve their performance and adopt continuous learning through the course of their careers.

Biomarkers Congress 2019 would provide a scientific platform for world-class professors, scientists, researchers, Oncologists, Radiologists, Hematologists, Immunologists, Neurologists, Cardiologists, & students, to exchange and share their experiences and research results on all aspects of Biomarkers, Cardiac Biomarkers, Neurological Biomarkers, Genomic Biomarkers, Immunological Biomarkers, Biomarkers in Pharmacology, Biomarkers in Oncology, Biomarkers in Drug Discovery & Development, Clinical Research and Clinical Trials. Biomarkers Congress 2019 designed on the theme: Awareness of Biomarkers & Clinical Research is inviting expert faculties from all over the world that will present practical clinical approaches to diagnostics and latest management strategies of challenging and controversial topics in Biomarkers research and Clinical research.

With immense pleasure, we would like to invite all the interested participants to join us for the event at Abu Dhabi. Abu Dhabi is one of the most attractive and beautiful cities in the Middle East; it is a city with a fantastic position. The view falls on all sides – commerce is reflected by the skyline’s modern towers and shopping megacenters such as Abu Dhabi and Marina malls and beneath white-marble domes, the vast Sheikh Zayed Grand Mosque features an immense Persian carpet. We are sure you will have a memorable time at the event as well as in the city.

We are looking forward to your association with Biomarkers Congress 2019.

For more details please visit:

Thursday, 3 January 2019


For many years, cancer treatment has traditionally focused on a tumor’s point of origin. A new form of immunotherapy for cancer that targets biomarkers could open the door for more precise and effective treatment of tumors.

Keytruda: A “Presidential” Immunotherapy for Cancer

Keytruda is the type of a drug that had previously been used to treat specific kinds of cancer such as melanoma and Hodgkin’s lymphoma, often during Stage IV. The drug earned public notice when former president Jimmy Carter received successful treatment for brain tumors resulting from Stage IV melanoma.

In May 2017, after five clinical trials, the Federal Drug Administration approved Keytruda for use in treating tumors with a particular biomarker, regardless of location. At this point, the new use of Keytruda is limited to patients for whom other therapies have been unsuccessful.

Cutting Through the Red Tape
The new application for Keytruda was fast-tracked under the FDA’s Accelerated Approval program. If there’s a serious condition with no options for treatment, a drug can be approved solely on the basis that it’s been shown to shrink tumors.

Dr. Gwen Nichols, chief medical officer of the Leukemia & Lymphoma Society” expressed excitement for the new approval process. According to Nichols, it lets researchers focus on the biology of tumor development instead of looking for generic treatments.

Immunotherapy for Cancer Is the Talk of the Medical Community

Doctors and scientists have been energetic about advancements in immunotherapy. Visit our website to learn more about our innovative immunotherapy for cancer treatments that are personally tailored to your individual needs.

Monday, 24 December 2018

Music and Meditation Alters Biomarkers of Alzheimer’s and Cellular Aging

 International Conference on 

Biomarkers and Clinical Research

S Summary: According to scientists, meditation and listening to music may help to alter biomarkers associated with cellular aging and Alzheimer’s disease in adults experiencing memory loss.
A research team led by Dr. Kim Innes, a professor in the West Virginia University School of Public Health, has found that a simple meditation or music listening program may alter certain biomarkers of cellular aging and Alzheimer’s Disease in older adults who are experiencing memory loss. Study findings, reported in the Journal of Alzheimer’s Disease, also suggest these changes may be directly related to improvements in memory and cognition, sleep, mood, and quality of life.

Sixty older adults with subjective cognitive decline (SCD), a circumstance that may represent a preclinical level of Alzheimer’s sickness, participated in the randomized, scientific trial. Whilst SCD has been connected to multiple risk for dementia and associated with certain neuropathological adjustments implicated in Alzheimer’s sickness development, together with expanded brain levels of beta-amyloid, this preclinical length may additionally provide an important window for therapeutic intervention.

In this trial, every participant becomes randomly assigned to either an amateur meditation (Kirtan Kriya) or tune listening software and requested to practice 12 minutes/day for 12 weeks. At baseline and three months, blood samples had been amassed.  Markers of mobile growing old have been measured: telomere duration and telomerase interest. Blood levels of specific beta-amyloid peptides commonly connected to Alzheimer’s sickness were also assessed. Further, reminiscence and cognitive function, stress, sleep, temper, and high-quality lifestyles had been measured. All members have been accompanied by a total of 6 months.

Following of completion of the 3 month intervention duration, the meditation organization showed substantially greater will increase in a key beta amyloid peptide (Aβ40) than did the music group. rising beta amyloid tiers have been correlated with enhancements in memory and cognitive characteristic, as well as with those in the mood, sleep, and first-rate of lifestyles at both three and six months; these high-quality associations had been considerably extra reported within the meditation institution. Telomerase hobby rose in each the meditation and track agencies, even though the will increase were great only among individuals who had decrease values at baseline (≤50th centile), and who practiced more often over the route of the intervention. Likewise, will increase in telomere duration had been also appreciably more among contributors with lower values at the start of the examine. Increases in telomere period and telomerase pastime have been also correlated with enhancements in certain cognitive and psychosocial effects.

in addition, both activities improved substantially in memory and cognitive feature, as well as in sleep and psychological status, even though upgrades in pressure, temper, and pleasant of life have been notably greater in the meditation institution. These improvements have been maintained or similarly strengthened at six months, three months after the intervention ended.

We are looking forward to your association with Biomarkers Congress 2019.

Friday, 14 December 2018

Heart Disease Biomarkers and Screening Tests

Cardiovascular or cardiac diseases are the leading cause of death worldwide, as mortality rates increase steadily due to the aging of the population. As such, it is important for key players in the field of medicine to detect the early symptoms of such conditions and to provide an empirical profile of biomarkers of heart disease.

Heart Disease Biomarkers

Biomarkers are present in many types of diseases, and their identification is an important aspect of health management since it facilitates the early detection of a certain disease and the prevention of a full-blown medical condition. Among heart conditions, biomarkers could be divided into several categories due to a large number of diseases associated with the disease. However, researchers have discovered that in many heart conditions, blood pressure and cholesterol levels are often real risk factors.

Screening Tests for Heart Diseases

Even with the presence of modern medical technologies, the process of detecting heart disease remains a challenge. However, the advent of biomarker research in cardiovascular diseases has been a great leap in the characterization and development of new techniques for detecting heart disease.

Screening Tests for Heart Disease Diagnosis

Doctors notice key symptoms in the diagnosis of certain heart conditions; however, a confirmatory test would always be recommended to ensure the correct diagnosis and appropriate treatment strategies. Several screening tests are available for the diagnosis of heart disease.
Electrocardiogram (EGC) -a device that uses electrical signals to observe heart rhythm and structure
Echocardiogram: a non-invasive technique that performs ultrasound in the chest area
Cardiac computed tomography (CT) scan: a collection of images around the heart to provide a complete cardiac figure
Cardiac magnetic resonance imaging (MRI): similar to computed tomography, an image of the heart is acquired for evaluation.

Key screening tests for the monitoring of heart disease

The treatment for a certain heart disease does not stop after the operation or medication. 
As part of cardiovascular management, doctors will always want to monitor heart condition after treatment. These are facilitated by a series of methods by measuring the levels of blood pressure, cholesterol, body weight, blood glucose levels and introducing physical activity or diet.

Grace your valuable presence at International Conference on Biomarkers and Clinical Research during January 30-31, 2019 in Abu Dhabi, UAE for more recent updates in Biomarkers and Clinical Research.

Wednesday, 12 December 2018

What Are Biomarkers and Why Are They Useful?

Biomarker is short for biological marker and is used as an indication that a biological process in the body has taken place or is commenced. While some biomarkers are used to show that the body has been exposed to a chemical, toxin or other environmental impacts - most related biomarkers with medication. Biomarkers are not medical symptoms such as a high temperature that a patient can use to determine how well they are, but an increased heart rate due to physical exertion is a biomarker. The enlarged heart rate is a biological response to the exercise.

Medical use of Biomarkers
There are many medical uses of biomarkers and the use of biomarkers will be significantly stretched as modified medical care becomes standard. Biomarkers can be used to find out what will happen to you when you use a particular treatment, or not to use it, and the risk of your emerging certain medical conditions.

Diagnostic use of Biomarkers

An example of the diagnostic use of biomarkers is the measurement of biomarkers in blood to determine if you have had a heart attack. Measuring the levels of enzymes, hormones and proteins in your blood allows the doctor to determine the severity of your heart attack and how much damage your heart has suffered.

A simple blood sample can be analyzed and the levels of marker chemicals measured. In the case of a heart attack, a doctor may examine the following:

Cardiac troponin is a protein that enters the bloodstream shortly after a heart attack and stays there when other biomarkers return to normal levels.
• Creatine kinase is an enzyme that increases concentration after a heart attack. A definite type of CK can be measured to determine the damage to the heart.

Biomarker levels can change over time and appear and disappear in different stages after an attack.

Which Medicine should I take?

It is in the area of dealings that biomarkers can have the major potential benefit. Researchers are constantly observing for new and more sensitive biomarkers to help make preventative and personalized treatments.

Defensive biomarkers show the risk of a person getting a particular disease; for example, a genetic mutation is currently used to indicate the increased risk of getting breast cancer. To get how researchers advance methods for biomarkers, read this article: Formation of the Saliva Volatomic Profile as an Exploratory and Non-invasive Strategy to Find Potential Breast Cancer Biomarkers.

Grace your valuable presence at International Conference on Biomarkers and Clinical Research during January 21-22, 2019 in Dubai, UAE for more recent updates in Biomarkers and Clinical Research.

For details contact:
Stella Jordan
Program Manager-Biomarkers Congress 2019


Friday, 30 November 2018

How Can Biomarkers Be Integrated Into Clinical Development To Enhance Value?

In general, a biomarker can be merged into a clinical development program in two ways. In the first, genome-wide association studies can be used to detect a biomarker signature that corresponds to a healthy drug response. Because this method is indirect it may be affected by multiple factors, including population and geographic modifications in biomarker spreading. Therefore, this approach is less likely to deliver value to either the payer or the pharma company.
In another, more ideal, method, the biomarker is directly associated with the method of the drug’s action. This is characteristic for directed oncology drugs, in which the biomarker may be the drug target itself. Such is the case with epidermal growth factor receptor (EGFR) inhibitors (e.g., erlotinib) and human epidermal growth factor receptor 2 (HER2) inhibitors (e.g., pertuzumab). In other cases, the biomarker may classify additional protein in the drug’s act pathway whose alteration allows the tumor to escape the drug’s effect (e.g., RAS mutation as a contraindication for the HER2-targeting drug panitumumab).

In each case, the connection of the biomarker measurement with drug activity is first determined in nonclinical (in vitro) studies and then undergoes an initial calculation in early clinical studies.
Provided with these initial data, the drug developer can project and execute the essential trials using a clinical trial assay to include or exclude patients based on a biomarker measurement that indicates likely drug response. This, in turn, establishes the basis for an expectation of enhanced value for the drug developer (higher likelihood of trial success; support for a higher drug price) as well as the payer (biomarker-enabled ability to grant drug access only to likely responders).
International Conference on Biomarkers and Clinical Research scheduled to be held during January 30-31, 2019 at Abu Dhabi, UAE would cover a broad session focusing on Biomarkers and Clinical research. We invite all the academic leaders, educationalists and, clinicians as well as for professionals and scholars of higher education from all over the world to con-vane and share novel ideas for a healthy life.
For more details visit our website:

Wednesday, 17 October 2018


About Conference

With Immense pleasure Biomarkers Congress-2019 invites all the participants across the globe to attend the “International Conference on Biomarkers and Clinical Research” during January 30-31, 2019 at Abu Dhabi, UAE. Biomarkers Congress-2019 will uncover different facets of Biomarker study from research to therapy and its applications in divergent fields of Clinical Sciences.

Theme: Awareness of Biomarkers & Clinical Research
This conference aims to bring together leading academic scientists, researchers and research scholars to exchange and share their experiences and research results on all aspects of Biomarkers and Clinical Research. Biomarkers have the extra potential to identify individuals susceptible to particular diseases. Biomarkers Congress-2019, in the hands of clinical investigators, provide a dynamic and powerful approach to understanding the spectrum of diseases with obvious applications in analytic epidemiology, biomarkers and clinical research in disease prevention, diagnosis and disease management. The cancer biomarker conferences are very much invigorated to extend the knowledge of continuous exposes and scientific research updates in these days. All advances can be evidenced in this biomarker congress.

Conference Highlights

Special Issues

  •  All accepted abstracts will be published in respective Supporting International Journals.
  •  Abstracts will be provided with Digital Object Identifier by Cross Ref.